ImmunityBio, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ImmunityBio, Inc. (NASDAQ: IBRX) develops next-generation immunotherapies that bolster the natural immune system to fight cancers and infectious diseases; its platforms include antibody-cytokine fusion proteins such as the FDA-approved Anktiva (N-803/nogapendekin alfa inbakicept-pmln), an IL-15 superagonist used in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ; vaccine vectors encompassing DNA, RNA, and adenovirus-based technologies for personalized cancer vaccines and HPV-related therapies; and cell therapies featuring NK-92-derived natural killer cells like PD-L1 t-haNK, alongside T-cell therapies and macrophage activators that target solid tumors (pancreatic, lung, colorectal), liquid tumors, HIV, and Lynch syndrome-associated cancers. The company, founded in 2014 and headquartered in San Diego, California, with additional operations in Culver City, California, and Morrisville, North Carolina, operates as a vertically integrated, commercial-stage biotechnology firm conducting internal cGMP manufacturing and a robust clinical pipeline across multiple phases and indications in collaboration with the National Cancer Institute, Serum Institute of India Private Limited, and BeiGene, Ltd. Recent developments include FDA approval of Anktiva in April 2024, an $80 million equity financing via registered direct offering with institutional investors in July 2025 to support operations and clinical trials, and a partnership with nCartes announced in November 2024 to automate clinical trial data processes.
ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)
ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
ImmunityBio: A Long-Term Bull Case Worth Watching
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
IBRX and the BCG Shortage: Deals That Could Expand Demand
ImmunityBio: Anktiva Explained and What Comes Next
IBRX Stock Outlook After Q1 Results and a New FDA Review
The $13 Million Company Teaching the Immune System to Hunt Cancer
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
DEADLINE ALERT for SMCI, IBRX, and PINS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX
IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman
IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman